Plant Name: Heliotropium angiospermum
Taxonomic Information:
Plant ID: NPO12589
Plant Latin Name: Heliotropium angiospermum
Taxonomy Genus: Heliotropium
Taxonomy Family: Heliotropiaceae
Plant External Links:
NCBI TaxonomyDB:
168338
Plant-of-the-World-Online:
116662-1
Used in Medicines:
Country/Region:
NetherlandsTraditional Medicine System:
Geographical Distribution:
Brazil; Jamaica; Bolivia; Honduras; Peru; Cuba; Venezuela; Mexico; Bahamas; Trinidad and Tobago; Netherlands; Colombia; Dominican Republic; Belize; Nicaragua; Haiti; Ecuador; United States
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; HRH3; ADRA2A; | |
| TSHR; | |
| NR3C1; | |
| NFKB1; HIF1A; | |
| KMT2A; | |
| MAPT; SERPINA6; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | HRH3 | Histamine H3 receptor | Q9Y5N1 | CHEMBL264 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 8.994E-07 | 5.776E-03 | HIF1A, MAPT, NR3C1 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.061E-06 | 5.776E-03 | ADRA2A, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.121E-06 | 7.199E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.121E-06 | 7.199E-03 | ADRA2A, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0045761; regulation of adenylate cyclase activity | 2.561E-06 | 7.199E-03 | ADRA2A, HRH3, TSHR |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 8.466E-06 | 1.121E-02 | ADRA2A, ADRA2C, HIF1A, NFKB1, SERPINA6 |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 9.886E-06 | 1.121E-02 | ADRA2A, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 9.886E-06 | 1.121E-02 | ADRA2A, ADRA2C |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 2.327E-05 | 1.635E-02 | SMN1, SMN2 |
| CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 2.749E-05 | 1.710E-02 | SMN1, SMN2 |
| MF | GO:0005488; binding | GO:0031690; adrenergic receptor binding | 5.383E-05 | 2.494E-02 | ADRA2A, ADRA2C |
| CC | GO:0044464; cell part | GO:0034719; SMN-Sm protein complex | 5.383E-05 | 2.494E-02 | SMN1, SMN2 |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 7.254E-05 | 2.976E-02 | ADRA2A, ADRA2C, KMT2A, MAPT, NFKB1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 3.596E-07 | 2.373E-05 | HRH3, ADRA2C, NR3C1, ADRA2A, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.676E-03 | 5.531E-02 | HIF1A, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 4.330E-03 | 6.614E-02 | ADRA2C, ADRA2A |
| 09120 Genetic Information Processing | 09122 Translation | hsa03013 | RNA transport | 4.586E-03 | 6.614E-02 | SMN2, SMN1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 6.089E-03 | 6.697E-02 | NFKB1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 5.010E-03 | 6.614E-02 | KMT2A, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 9.824E-03 | 9.262E-02 | MAPT, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 4.006E-02 | 9.388E-02 | NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 4.237E-02 | 9.388E-02 | NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 4.294E-02 | 9.388E-02 | NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; NR3C1; SERPINA6; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; NR3C1; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; HRH3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | NR3C1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; NR3C1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HRH3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HRH3; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; HRH3; |
| NA: NA | Obstructive airway diseases | NA | SERPINA6; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HRH3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Narcolepsy | G47.4 | HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obese insulin-resistant disorders | E11 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Excessive daytime sleepiness | F51.1, G47.1 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | NR3C1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | NR3C1; SERPINA6; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; NR3C1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; |
| NA: NA | Non-infectious rhinitis | NA | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; HRH3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | NR3C1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HRH3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | HRH3; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | NR3C1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | NR3C1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | NR3C1; HRH3; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; HIF1A; NR3C1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; HRH3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; NR3C1; HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; HRH3; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2A; ADRA2C; HRH3; |
| H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
